AIMS: Fingolimod, oral treatment for relapsing-remitting multiple sclerosis (RRMS), is an agonist of sphingosine and its metabolite S1P that binds their receptors, blocking the egress of lymphocytes from lymph nodes. The aim of this study was immunomonitoring of minor peripheral lymphocyte subpopulations in RRMS patients under treatment with fingolimod and correlation with treatment response. METHODS: Prospective study. T- and B-cell subpopulations were analyzed using multiparametric flow cytometry in peripheral blood from 14 RRMS patients under treatment with fingolimod at baseline, +1, +3, +6, +9, and +12 months of follow-up. Response to therapy was assessed at month +12. RESULTS: Most changes in minor lymphocyte subpopulations occurred in the first month of treatment and were maintained until the end of follow-up. The basal percentages of recent thymic emigrants (RTEs) and transitional B cells were lower in responder patients than in nonresponders. After 1 month of follow-up, the percentages of late effector memory CD4(+) T cells in peripheral blood were higher in responder patients. CONCLUSION: If confirmed in a bigger cohort of patients, analysis of percentages of minor lymphocyte subpopulations in peripheral blood of patients with RRMS prior and after +1 month of treatment might predict clinical response to fingolimod.
AIMS: Fingolimod, oral treatment for relapsing-remitting multiple sclerosis (RRMS), is an agonist of sphingosine and its metabolite S1P that binds their receptors, blocking the egress of lymphocytes from lymph nodes. The aim of this study was immunomonitoring of minor peripheral lymphocyte subpopulations in RRMS patients under treatment with fingolimod and correlation with treatment response. METHODS: Prospective study. T- and B-cell subpopulations were analyzed using multiparametric flow cytometry in peripheral blood from 14 RRMS patients under treatment with fingolimod at baseline, +1, +3, +6, +9, and +12 months of follow-up. Response to therapy was assessed at month +12. RESULTS: Most changes in minor lymphocyte subpopulations occurred in the first month of treatment and were maintained until the end of follow-up. The basal percentages of recent thymic emigrants (RTEs) and transitional B cells were lower in responder patients than in nonresponders. After 1 month of follow-up, the percentages of late effector memory CD4(+) T cells in peripheral blood were higher in responder patients. CONCLUSION: If confirmed in a bigger cohort of patients, analysis of percentages of minor lymphocyte subpopulations in peripheral blood of patients with RRMS prior and after +1 month of treatment might predict clinical response to fingolimod.
Authors: M C Kowarik; H L Pellkofer; S Cepok; T Korn; T Kümpfel; D Buck; R Hohlfeld; A Berthele; B Hemmer Journal: Neurology Date: 2011-04-05 Impact factor: 9.910
Authors: M Mehling; V Brinkmann; J Antel; A Bar-Or; N Goebels; C Vedrine; C Kristofic; J Kuhle; R L P Lindberg; L Kappos Journal: Neurology Date: 2008-10-14 Impact factor: 9.910
Authors: Chris H Polman; Stephen C Reingold; Brenda Banwell; Michel Clanet; Jeffrey A Cohen; Massimo Filippi; Kazuo Fujihara; Eva Havrdova; Michael Hutchinson; Ludwig Kappos; Fred D Lublin; Xavier Montalban; Paul O'Connor; Magnhild Sandberg-Wollheim; Alan J Thompson; Emmanuelle Waubant; Brian Weinshenker; Jerry S Wolinsky Journal: Ann Neurol Date: 2011-02 Impact factor: 10.422
Authors: Bibiana Quirant-Sánchez; José V Hervás-García; Aina Teniente-Serra; Luis Brieva; Ester Moral-Torres; Antonio Cano; Elvira Munteis; María J Mansilla; Silvia Presas-Rodriguez; Juan Navarro-Barriuso; Cristina Ramo-Tello; Eva M Martínez-Cáceres Journal: CNS Neurosci Ther Date: 2018-04-15 Impact factor: 5.243
Authors: Nirupama D Verma; Andrew D Lam; Christopher Chiu; Giang T Tran; Bruce M Hall; Suzanne J Hodgkinson Journal: Sci Rep Date: 2021-05-18 Impact factor: 4.379
Authors: Sarah Harris; Jonathan Q Tran; Harry Southworth; Collin M Spencer; Bruce A C Cree; Scott S Zamvil Journal: Neurol Neuroimmunol Neuroinflamm Date: 2020-07-31